• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F).JAK2 FERM 结构域在 JAK2(V617F)过度激活中的调节作用。
Biochem J. 2010 Jan 27;426(1):91-8. doi: 10.1042/BJ20090615.
2
Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation.激活环酪氨酸使JAK2(V617F)突变体实现超激活。
Cell Biochem Biophys. 2008;52(2):103-12. doi: 10.1007/s12013-008-9025-4.
3
Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.JAK2 V617 突变体抑制策略对细胞因子受体信号的差异影响。
J Allergy Clin Immunol. 2019 Jul;144(1):224-235. doi: 10.1016/j.jaci.2018.12.1023. Epub 2019 Jan 29.
4
Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.促红细胞生成素受体中的三个酪氨酸残基对Janus激酶2 V617F突变体诱导的肿瘤发生至关重要。
J Biol Chem. 2017 Feb 3;292(5):1826-1846. doi: 10.1074/jbc.M116.749465. Epub 2016 Dec 20.
5
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.ATP与JAK2假激酶结构域的结合对于致病性激活至关重要。
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4642-7. doi: 10.1073/pnas.1423201112. Epub 2015 Mar 30.
6
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.JAK2 激活的分子基础:促红细胞生成素受体和致病性 JAK2 信号转导。
Sci Adv. 2024 Mar 8;10(10):eadl2097. doi: 10.1126/sciadv.adl2097.
7
Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2.Jak2的FERM结构域中通过自身磷酸化实现细胞因子信号传导的受体特异性下调。
EMBO J. 2006 Oct 18;25(20):4763-72. doi: 10.1038/sj.emboj.7601365. Epub 2006 Oct 5.
8
Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.衔接蛋白 Lnk 的表达水平和差异 JAK2-V617F 结合调节骨髓增殖性肿瘤中的 JAK2 介导的信号。
Blood. 2010 Dec 23;116(26):5961-71. doi: 10.1182/blood-2009-12-256768. Epub 2010 Sep 24.
9
Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.酪氨酸磷酸化的 SOCS3 负调控由骨髓增殖性肿瘤相关 JAK2 V617F 突变体介导的细胞转化。
Cytokine. 2019 Nov;123:154753. doi: 10.1016/j.cyto.2019.154753. Epub 2019 Jun 27.
10
New insights into the structure and function of the pseudokinase domain in JAK2.新型伪激酶结构域在 JAK2 中的结构与功能的深入研究。
Biochem Soc Trans. 2013 Aug;41(4):1002-7. doi: 10.1042/BST20130005.

引用本文的文献

1
Essential contribution of the JAK/STAT pathway to carcinogenesis, lytic infection of herpesviruses and pathogenesis of COVID‑19 (Review).JAK/STAT 通路在致癌作用、疱疹病毒的裂解感染和 COVID-19 发病机制中的重要作用(综述)。
Mol Med Rep. 2024 Mar;29(3). doi: 10.3892/mmr.2024.13163. Epub 2024 Jan 19.
2
Molecular landscape of the gene in chronic myeloproliferative neoplasm patients from the state of Amazonas, Brazil.巴西亚马孙州慢性骨髓增殖性肿瘤患者中该基因的分子图谱。
Biomed Rep. 2023 Oct 23;19(6):98. doi: 10.3892/br.2023.1680. eCollection 2023 Dec.
3
The Contribution of 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms.46/1 单体型在骨髓增殖性肿瘤易感性中的作用。
Int J Mol Sci. 2022 Oct 20;23(20):12582. doi: 10.3390/ijms232012582.
4
Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.急性淋巴细胞白血病的改变:卓越精准医学策略的分子见解
Front Cell Dev Biol. 2022 Jul 12;10:942053. doi: 10.3389/fcell.2022.942053. eCollection 2022.
5
Identification of a FERM Domain Variant Associated With Hereditary Thrombocytosis.一种与遗传性血小板增多症相关的FERM结构域变体的鉴定。
Hemasphere. 2021 Aug 2;5(8):e626. doi: 10.1097/HS9.0000000000000626. eCollection 2021 Aug.
6
Baricitinib: From Rheumatoid Arthritis to COVID-19.巴瑞替尼:从类风湿关节炎到 COVID-19。
J Clin Pharmacol. 2021 Oct;61(10):1274-1285. doi: 10.1002/jcph.1874. Epub 2021 Jun 12.
7
Janus Kinases in Leukemia.白血病中的Janus激酶
Cancers (Basel). 2021 Feb 14;13(4):800. doi: 10.3390/cancers13040800.
8
Nanoparticles Targeting STATs in Cancer Therapy.纳米颗粒在癌症治疗中靶向 STATs。
Cells. 2019 Sep 27;8(10):1158. doi: 10.3390/cells8101158.
9
Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.系统性红斑狼疮中 JAK/STAT 信号的致病和治疗相关性:不同炎症途径的整合及其通过口服药物抑制的前景
Cells. 2019 Aug 15;8(8):898. doi: 10.3390/cells8080898.
10
Polyphosphoinositide-Binding Domains: Insights from Peripheral Membrane and Lipid-Transfer Proteins.多聚磷酸肌醇结合结构域:外周膜和脂质转位蛋白的研究进展。
Adv Exp Med Biol. 2019;1111:77-137. doi: 10.1007/5584_2018_288.

本文引用的文献

1
Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation.Jak1的FERM结构域和激酶结构域在细胞因子受体结合及刺激依赖性Jak激活中的双重作用。
J Immunol. 2008 Jan 15;180(2):998-1007. doi: 10.4049/jimmunol.180.2.998.
2
Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity.Jak2的FERM结构域与促红细胞生成素受体的相互作用调节Jak2激酶活性。
Mol Cell Biol. 2008 Mar;28(5):1792-801. doi: 10.1128/MCB.01447-07. Epub 2007 Dec 26.
3
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.细胞因子受体介导的二聚化对于JAK2V617F的组成性激活是必需的。
J Biol Chem. 2008 Feb 29;283(9):5258-66. doi: 10.1074/jbc.M707125200. Epub 2007 Dec 23.
4
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.JAK2在骨髓增殖性疾病发病机制及治疗中的作用。
Nat Rev Cancer. 2007 Sep;7(9):673-83. doi: 10.1038/nrc2210.
5
Structural basis for the autoinhibition of focal adhesion kinase.粘着斑激酶自身抑制的结构基础。
Cell. 2007 Jun 15;129(6):1177-87. doi: 10.1016/j.cell.2007.05.041.
6
The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and -independent mechanisms.血小板生成素受体的膜近端区域通过依赖JAK2和不依赖JAK2的机制赋予其高表面表达。
J Biol Chem. 2006 Dec 15;281(50):38930-40. doi: 10.1074/jbc.M607524200. Epub 2006 Oct 19.
7
Emerging roles of pseudokinases.伪激酶的新作用
Trends Cell Biol. 2006 Sep;16(9):443-52. doi: 10.1016/j.tcb.2006.07.003. Epub 2006 Aug 1.
8
Jaks and cytokine receptors--an intimate relationship.Jaks与细胞因子受体——密切关系。
Biochem Pharmacol. 2006 Nov 30;72(11):1538-46. doi: 10.1016/j.bcp.2006.04.013. Epub 2006 Apr 27.
9
Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling.Jak2蛋白在丝氨酸523位点的磷酸化抑制Jak2依赖的瘦素受体信号传导。
Mol Cell Biol. 2006 Jun;26(11):4063-73. doi: 10.1128/MCB.01589-05.
10
Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor.JAK2在丝氨酸523处的磷酸化:一种受生长激素和表皮生长因子刺激的JAK2负调节因子。
Mol Cell Biol. 2006 Jun;26(11):4052-62. doi: 10.1128/MCB.01591-05.

JAK2 FERM 结构域在 JAK2(V617F)过度激活中的调节作用。

A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F).

机构信息

Department of Cell Biology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, U.S.A.

出版信息

Biochem J. 2010 Jan 27;426(1):91-8. doi: 10.1042/BJ20090615.

DOI:10.1042/BJ20090615
PMID:19929856
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8514084/
Abstract

JAK2 (Janus tyrosine kinase 2) is important for signalling through many cytokine receptors, and a gain-of-function JAK2 mutation in its pseudokinase domain, V617F, has been implicated in Philadelphia chromosome-negative myeloproliferative neoplasms. How this mutation hyperactivates JAK2 is poorly understood. In the present paper we report our findings that the V617F mutation has little effect on the Vmax of JAK2 kinase activity, but lowers the Km value for substrates. Therefore under physiological conditions where the concentration level of substrates is presumably below saturation, JAK2(V617F) exhibits hyperactivation compared with wild-type JAK2. This lower Km of JAK2(V617F) towards substrates requires the JAK2 FERM (4.1/ezrin/radixin/moesin) domain, as deletion of the FERM domain abolished this effect. We also show that, in contrast with its positive role in JAK2(V617F) hyperactivation, the FERM domain in wild-type JAK2 is inhibitory. Deletion or mutations of the FERM domain resulted in increased basal JAK2 kinase activity. The results of the present study provide the biochemical basis for how V617F hyperactivates JAK2, and identifies novel regulating roles of the JAK2 FERM domain to control kinase activity at different activation states.

摘要

JAK2(Janus 酪氨酸激酶 2)对于许多细胞因子受体的信号传递很重要,其假激酶结构域中的功能获得性 JAK2 突变 V617F 与费城染色体阴性骨髓增殖性肿瘤有关。这种突变如何使 JAK2 过度激活还不太清楚。在本文中,我们报告了我们的发现,即 V617F 突变对 JAK2 激酶活性的 Vmax 影响很小,但降低了底物的 Km 值。因此,在生理条件下,底物的浓度水平可能低于饱和状态,与野生型 JAK2 相比,JAK2(V617F)表现出过度激活。JAK2(V617F)对底物的这种较低 Km 值需要 JAK2 FERM(4.1/ezrin/radixin/moesin)结构域,因为缺失 FERM 结构域会消除这种效应。我们还表明,与 JAK2(V617F)过度激活的积极作用相反,野生型 JAK2 中的 FERM 结构域具有抑制作用。FERM 结构域的缺失或突变导致基础 JAK2 激酶活性增加。本研究的结果为 V617F 如何过度激活 JAK2 提供了生化基础,并确定了 JAK2 FERM 结构域在不同激活状态下控制激酶活性的新调节作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/606184cc9480/nihms-1743625-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/74f150291af8/nihms-1743625-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/3a545625192c/nihms-1743625-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/3e0c3ad22d3f/nihms-1743625-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/446c9e838e64/nihms-1743625-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/606184cc9480/nihms-1743625-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/74f150291af8/nihms-1743625-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/3a545625192c/nihms-1743625-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/3e0c3ad22d3f/nihms-1743625-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/446c9e838e64/nihms-1743625-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d45/8514084/606184cc9480/nihms-1743625-f0005.jpg